Therapeutics, drug discovery, and the platforms behind them — private biotech ranked by valuation.
| # | Company | Valuation | Secondary $/sh | vs Last Round | Last Round | IPO Status |
|---|---|---|---|---|---|---|
| 1 | Colossal Biosciences Dallas, Texas |
$30Bmark 2026-07 | $8.50as of 2026-06-27 | -65.8% | Series C extension · 2025-09-17 · $120M | Private |
| 2 | Biosplice Therapeutics San Diego, CA |
$12Bmark 2018-Q3 | no secondary mark | — | Series E · 2018-08-15 · $438M | no imminent plans |
| 3 | Isomorphic Labs London, UK |
$12Bmark 2026-Q2 | $61.50as of 2026-06-27 | no priced round on record | Series B · 2026-05-12 · $2.1B | no imminent plans |
| 4 | Resilience Blue Ash, OH |
$9.4Bmark 2023-Q1 | no secondary mark | — | Series D · 2023-01-04 · $625M | no imminent plans |
| 5 | Neuralink Fremont, California |
$9.0Bmark 2026-08 | no secondary mark | — | Series E · 2025-06-01 · $650M | none |
| 6 | Lila Sciences Cambridge, MA |
$8.5Bmark 2026-06 | no secondary mark | — | undisclosed | private |
| 7 | Ro New York, NY |
$7.0Bmark 2025 | no secondary mark | — | Series D · 2022-02-22 · $150M | rumored |
| 8 | Benchling San Francisco, USA |
$6.1Bmark 2021-Q4 | no secondary mark | — | Series F · 2021-11-18 · $100M | rumored |
| 9 | SandboxAQ Palo Alto, CA |
$5.6Bmark 2026 | $21.35as of 2026-06-27 | +24.1% | Series E · 2025-04-03 · $450M | Private |
| 10 | Color Burlingame, CA |
$4.6Bmark 2021-Q4 | $12.24as of 2026-06-27 | -87.8% | Series E · 2021-11-08 · $100M | private |
| 11 | Sword Health New York, NY |
$4.5Bmark 2025-Q2 | $27.83as of 2026-06-27 | -61.1% | Series F · 2025-06-17 · $40M | private |
| 12 | Chai Discovery San Francisco, CA |
$3.8Bmark 2026-07 | $47.97as of 2026-06-27 | -29.1% | Growth · 2026-07-14 · $400M | private |
| 13 | Ultima Genomics Fremont, CA |
$3.6Bmark 2022-Q2 | $24.96as of 2026-06-27 | -50.2% | Series E · 2022-05-31 · $229M | private |
| 14 | Judi Health New York, NY |
$3.3Bmark 2025-Q3 | $15.12as of 2026-06-27 | +12.1% | Series F · 2025-09-08 · $400M | private |
| 15 | Eat Just Alameda, CA |
$2.6Bmark 2022-Q3 | $4.27as of 2026-06-27 | = last roundmark | Series F · 2022-08-17 · $25M | private |
| 16 | Insitro South San Francisco, CA |
$2.4Bmark 2021-Q1 | $12.94as of 2026-06-27 | -29.3% | Series C · 2021-03-19 · $400M | no imminent plans |
| 17 | Generate Biomedicines Somerville, MA |
$2.2Bmark 2026-02 | $5.75as of 2026-06-27 | no priced round on record | undisclosed | private |
| 18 | Solugen Omaha, NE |
$2.2Bmark 2022-Q4 | $33.46as of 2026-06-27 | -17.8% | Series D · 2022-10-28 · $200M | private |
| 19 | Freenome Brisbane, CA |
$2.2Bmark 2024-Q1 | $1.48as of 2026-06-27 | -80.0% | Later Stage VC · 2024-02-14 · $254M | private |
| 20 | Medable Palo Alto, CA |
$2.1Bmark 2021-Q4 | $3.00as of 2026-06-27 | -69.0% | Series D · 2021-10-24 · $304M | private |
| 21 | ArsenalBio South San Francisco, CA |
$1.9Bmark 2024-Q3 | $15.59as of 2026-06-27 | -16.1% | Series C · 2024-09-04 · $325M | private |
| 22 | Rightway New York, NY |
$1.8Bmark 2026-09-24 | no secondary mark | = last roundmark | Series E · 2026-09-24 · $155M | private |
| 23 | Formation Bio New York, NY |
$1.7Bmark 2024 | $2.61as of 2026-06-27 | -68.1% | undisclosed | private |
| 24 | Pivot Bio Berkeley, CA |
$1.7Bmark 2021-Q3 | $5.28as of 2026-06-27 | -30.4% | Series D · 2021-07-18 · $430M | private |
| 25 | Inari Cambridge, MA |
$1.6Bmark 2025-Q1 | $8.00as of 2026-06-27 | = last roundmark | Later Stage VC · 2025-01-07 · $144M | private |
| 26 | SonderMind Greensboro, NC |
$1.6Bmark 2021-Q2 | $21.00as of 2026-06-27 | +16.5% | Series C · 2021-05-27 · $242M | private |
| 27 | NewLimit South San Francisco, CA |
$1.6Bmark 2025-Q4 | $21.47as of 2026-06-27 | = last roundmark | Early Stage VC · 2025-10-19 · $45M | private |
| 28 | Science Alameda, CA |
$1.5Bmark 2026-Q1 | $4.76as of 2026-06-27 | = last roundmark | Series C · 2026-03-05 · $230M | private |
| 29 | Valo Health Lexington, MA |
$1.4Bmark 2022-Q4 | no secondary mark | = last roundmark | Series C · 2022-10-28 · $100M | private |
| 30 | RefleXion Medical Hayward, CA |
$1.3Bmark 2023-Q4 | no secondary mark | = last roundmark | Series F · 2023-11-15 · $107M | private |
| 31 | Owkin Paris, France |
$1.3Bmark 2021-Q4 | $36.88as of 2026-06-27 | -14.3% | Series B · 2021-11-18 · $180M | private |
| 32 | BioIntellisense Golden, CO |
$1.2Bmark 2022-Q4 | no secondary mark | = last roundmark | Early Stage VC · 2022-12-30 · $179M | private |
| 33 | Capsule New York, NY |
$1.2Bmark 2021-Q2 | no secondary mark | = last roundmark | Series D · 2021-04-28 · $300M | private |
| 34 | Orca Bio Menlo Park, CA |
$1.2Bmark 2020-Q2 | $38.00as of 2026-06-27 | +8.5% | Series D · 2020-06-17 · $192M | private |
| 35 | Modern Health San Francisco, CA |
$1.2Bmark 2025-10 | $21.40as of 2026-06-27 | -51.4% | Series C · 2025-10-01 · $74M | private |
| 36 | Enveda Biosciences Boulder, CO |
$1.2Bmark 2025-Q3 | no secondary mark | = last roundmark | Series D · 2025-09-04 · $150M | private |
| 37 | Kallyope New York, NY |
$1.1Bmark 2022-Q1 | no secondary mark | = last roundmark | Series D · 2022-01-27 · $236M | private |
| 38 | Adimab Lebanon, NH |
$1.1Bmark 2015-Q1 | $57.00as of 2026-06-27 | = last roundmark | Later Stage VC · 2015-01-31 · $100M | private |
| 39 | Guardian Bio | $1.1Bmark 2026-09 | no secondary mark | — | Pre-seed · 2022-08 · $1M | private |
| 40 | Thirty Madison New York, NY |
$1.0Bmark 2021-Q2 | $4.00as of 2026-06-27 | -79.2% | Series C · 2021-06-02 · $141M | private |
| 41 | Element Biosciences San Diego, CA |
$1.0Bmark 2024-Q3 | $4.00as of 2026-06-27 | -49.0% | Series D · 2024-07-10 · $277M | private |
| 42 | PathAI Boston, MA |
$1.0Bmark 2021-Q2 | $21.89as of 2026-06-27 | -25.8% | Series C · 2021-05-17 · $165M | private |
| 43 | Synchron Brooklyn, NY |
$1.0Bmark 2024-Q4 | $34.68as of 2026-06-27 | no priced round on record | Series C · 2024-12-01 · $75M | no imminent plans |
| 44 | Mammoth Biosciences Brisbane, CA |
$1.0Bmark 2021-Q3 | $4.38as of 2026-06-27 | -67.4% | Series D · 2021-09-01 · $195M | no imminent plans |
| 45 | Xaira Therapeutics South San Francisco, CA |
$1.0Bmark 2024-Q2 | $4.39as of 2026-06-27 | no priced round on record | Series A · 2024-04-23 · $1.0B | no imminent plans |
| 46 | Asimov Boston, MA |
$1.0Bmark 2026-02 | $82.00as of 2026-06-27 | -11.5% | Series B · 2026-02-01 · $175M | private |
| 47 | Truveta Bellevue, WA |
$1.0Bmark 2025-Q1 | no secondary mark | = last roundmark | Series C · 2025-01-13 · $320M | private |
| 48 | Midi Palo Alto, CA |
$1.0Bmark 2026-Q1 | $2.37as of 2026-06-27 | -76.4% | Series D · 2026-02-02 · $100M | private |
| 49 | Alloy Therapeutics Waltham, MA |
$1.0Bmark 2026-Q2 | no secondary mark | = last roundmark | Series E · 2026-04-15 · $40M | private |
| 50 | Axtria Berkeley Heights, NJ |
$1.0Bmark 2021-Q2 | no secondary mark | = last roundmark | Series E · 2021-04-30 · $150M | private |
vs Last Round — unlabeled: the secondary share price against the round's price per share (the tape's own comparison). print: the latest observed print's implied valuation against the last priced round's post-money. mark: the valuation shown against that post-money — no independent print yet. = last round means the two legs are within 0.5%; for a mark basis that means the valuation shown was set by the round itself. A cell that says no priced round on record has a secondary price but no round to test it against — it is never rendered as 0.
Ranked by tracked Biotech portfolio companies — counted from disclosed round participation and each firm's notable holdings, so a firm only appears here if it actually holds companies in this ranking. Full capital-side ranking: Top Private Market Investors by AUM.
By latest disclosed valuation, the largest tracked private Biotech companies are Colossal Biosciences ($30B), Biosplice Therapeutics ($12B), Isomorphic Labs ($12B), Resilience ($9.4B), Neuralink ($9.0B). The full ranking of 155 companies refreshes daily at quantlogix.ai/private/biotech.
Ranked by tracked Biotech portfolio companies, the most active investors are ARCH Venture Partners (8 tracked), Andreessen Horowitz (4 tracked), Thrive Capital (4 tracked), Sequoia Capital (3 tracked), RA Capital Management (3 tracked). Full ranking: Top Private Market Investors by AUM.
Valuations are each company's latest disclosed mark, dated per row; secondary share prices refresh daily (33 of 155 tracked companies currently carry one). Rows without a usable number say so rather than showing zero.
Methodology. Rankings are by each company's latest disclosed valuation (roster + weekly enrichment); the "mark" chip shows when that valuation was set. Secondary share prices are point estimates from secondary-market activity — one implied price per name, no bid/ask — refreshed daily (marks overlay as of 2026-10-01), each carrying its own date. "vs Last Round" compares the secondary price to the company's own last primary round per-share price; rows without a usable comparison say so rather than showing zero. Companies marked acquired, defunct, or public are excluded. Educational data, not investment advice.